Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 82; no. 4; pp. 575 - 577
Main Authors Dougados, Maxime, Charles-Schoeman, Christina, Szekanecz, Zoltán, Giles, Jon T, Ytterberg, Steven R, Bhatt, Deepak L, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Connell, Carol A, Yndestad, Arne, Rivas, Jose L, Buch, Maya H
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.04.2023
Elsevier Limited
BMJ Publishing Group
Subjects
Antirheumatic Agents
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid
Arthritis, Rheumatoid - chemically induced
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Cardiology
Cardiovascular disease
Cardiovascular Diseases
Cardiovascular Diseases - chemically induced
Clinical trials
Coronary vessels
Heart Disease Risk Factors
Humans
Incidence
Letter
Patients
Pyrroles - adverse effects
Rheumatoid arthritis
Risk Factors
Surveillance
Treatment Outcome
Vein & artery diseases
New York
United States > US
Antirheumatic Agents
Cardiovascular Diseases
Arthritis, Rheumatoid
Online AccessGet full text

Cover

Author Connell, Carol A
Bhatt, Deepak L
Buch, Maya H
Menon, Sujatha
Yndestad, Arne
Kwok, Kenneth
Charles-Schoeman, Christina
Rivas, Jose L
Ytterberg, Steven R
Wu, Joseph
Szekanecz, Zoltán
Dougados, Maxime
Vranic, Ivana
Giles, Jon T
Wang, Cunshan
Koch, Gary G
AuthorAffiliation 11 Pfizer Inc , New York , New York , USA
10 Pfizer Inc , Groton , Connecticut , USA
15 NIHR Manchester Biomedical Research Centre , Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK
7 Mount Sinai Heart , Icahn School of Medicine at Mount Sinai Health System , New York , New York , USA
6 Division of Rheumatology , Mayo Clinic , Rochester , Minnesota , USA
12 Pfizer Inc , Oslo , Norway
14 Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health , The University of Manchester , Manchester , UK
9 Pfizer Ltd , Tadworth , Surrey , UK
3 Division of Rheumatology, Department of Medicine , University of California Los Angeles , Los Angeles , California , USA
13 Pfizer SLU , Madrid , Spain
1 Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris , Université de Paris , Paris , France
8 Department of Biostatistics , University of North Caroli
AuthorAffiliation_xml – name: 5 Division of Rheumatology , Columbia University Vagelos College of Physicians and Surgeons , New York , New York , USA
– name: 13 Pfizer SLU , Madrid , Spain
– name: 1 Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris , Université de Paris , Paris , France
– name: 14 Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health , The University of Manchester , Manchester , UK
– name: 3 Division of Rheumatology, Department of Medicine , University of California Los Angeles , Los Angeles , California , USA
– name: 4 Division of Rheumatology, Faculty of Medicine , University of Debrecen , Debrecen , Hungary
– name: 15 NIHR Manchester Biomedical Research Centre , Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK
– name: 11 Pfizer Inc , New York , New York , USA
– name: 7 Mount Sinai Heart , Icahn School of Medicine at Mount Sinai Health System , New York , New York , USA
– name: 6 Division of Rheumatology , Mayo Clinic , Rochester , Minnesota , USA
– name: 8 Department of Biostatistics , University of North Carolina at Chapel Hill , Chapel Hill , North Carolina , USA
– name: 9 Pfizer Ltd , Tadworth , Surrey , UK
– name: 10 Pfizer Inc , Groton , Connecticut , USA
– name: 12 Pfizer Inc , Oslo , Norway
– name: 2 INSERM (U1153): Clinical Epidemiology and Biostatistics , PRES Sorbonne Paris-Cité , Paris , France
Author_xml – sequence: 1
  givenname: Maxime
  orcidid: 0000-0003-3009-6229
  surname: Dougados
  fullname: Dougados, Maxime
  email: maxime.dougados@aphp.fr
  organization: INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
– sequence: 2
  givenname: Christina
  surname: Charles-Schoeman
  fullname: Charles-Schoeman, Christina
  organization: Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
– sequence: 3
  givenname: Zoltán
  orcidid: 0000-0002-7794-6844
  surname: Szekanecz
  fullname: Szekanecz, Zoltán
  organization: Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
– sequence: 4
  givenname: Jon T
  surname: Giles
  fullname: Giles, Jon T
  organization: Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
– sequence: 5
  givenname: Steven R
  surname: Ytterberg
  fullname: Ytterberg, Steven R
  organization: Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
– sequence: 6
  givenname: Deepak L
  surname: Bhatt
  fullname: Bhatt, Deepak L
  organization: Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA
– sequence: 7
  givenname: Gary G
  surname: Koch
  fullname: Koch, Gary G
  organization: Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
– sequence: 8
  givenname: Ivana
  surname: Vranic
  fullname: Vranic, Ivana
  organization: Pfizer Ltd, Tadworth, Surrey, UK
– sequence: 9
  givenname: Joseph
  surname: Wu
  fullname: Wu, Joseph
  organization: Pfizer Inc, Groton, Connecticut, USA
– sequence: 10
  givenname: Cunshan
  surname: Wang
  fullname: Wang, Cunshan
  organization: Pfizer Inc, Groton, Connecticut, USA
– sequence: 11
  givenname: Kenneth
  surname: Kwok
  fullname: Kwok, Kenneth
  organization: Pfizer Inc, New York, New York, USA
– sequence: 12
  givenname: Sujatha
  surname: Menon
  fullname: Menon, Sujatha
  organization: Pfizer Inc, Groton, Connecticut, USA
– sequence: 13
  givenname: Carol A
  surname: Connell
  fullname: Connell, Carol A
  organization: Pfizer Inc, Groton, Connecticut, USA
– sequence: 14
  givenname: Arne
  surname: Yndestad
  fullname: Yndestad, Arne
  organization: Pfizer Inc, Oslo, Norway
– sequence: 15
  givenname: Jose L
  surname: Rivas
  fullname: Rivas, Jose L
  organization: Pfizer SLU, Madrid, Spain
– sequence: 16
  givenname: Maya H
  orcidid: 0000-0002-8962-5642
  surname: Buch
  fullname: Buch, Maya H
  organization: NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36720582$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhi1URLeFMzdkiQsSCvVHYmdPCFUFKlXiAmfLcSZdL7G92MlK_BL-bifaUmAlerE1M887mq8zchJTBEJecvaOc6kubO4rwYSohJA1U0_IiteqRZdiJ2TFGJNVvVb6lJyVskWTtbx9Rk6l0oI1rViRX9dhZ91E00AdJvNpb4ubR5tp9uU7hZi92wSISETqo_M9RAcLHuw2ZWr7PeQCx2LYo6SggE4boFMarPOTj76jeQNzsFPyPbV52mR0F-pGjDk70l1Ot9mGAM_J08GOBV7c_-fk28err5efq5svn64vP9xUXd2qqepc54a-rgclJPash7rXMPRCdNB2aArQirkGFAeG77oTwvGBiVpoiYOy8py8P-TdzV2A3mHZ2Y5ml32w-adJ1pt_I9FvzG3aG46zVGItMMOb-ww5_ZihTCb44mAcbYQ0FyO05koqJiSir4_QbZpzxP6QaptWcy3axynNebOWcqFe_V34Q8W_V4vAxQFwOZWSYXhAODPL8RhcmVmOxxyOBxXNkQKXZiefls79-Iju7UHXhe2fWv9H3wGfQNlY
CitedBy_id crossref_primary_10_3390_jpm13091303
crossref_primary_10_5114_reum_175626
crossref_primary_10_1007_s40264_023_01333_0
crossref_primary_10_1038_s41584_023_01062_9
crossref_primary_10_1007_s40744_024_00662_5
crossref_primary_10_3390_jpm14070712
crossref_primary_10_37349_emd_2024_00051
crossref_primary_10_1038_s41584_024_01153_1
crossref_primary_10_1016_j_ard_2025_01_024
crossref_primary_10_1016_j_gastrohep_2024_502314
Cites_doi 10.1136/ard-2022-222259
10.1016/j.semarthrit.2016.05.014
10.1056/NEJMoa2109927
10.1136/annrheumdis-2016-209775
10.1136/rmdopen-2021-001595
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023
Copyright_xml – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023
DBID 9YT
ACMMV
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1136/ard-2022-223406
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
BMJ Journals
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 577
ExternalDocumentID PMC10086292
36720582
10_1136_ard_2022_223406
annrheumdis
Genre Letter
Research Support, Non-U.S. Gov't
Correspondence
Letter to the Editor
GeographicLocations New York
United States--US
GeographicLocations_xml – name: New York
– name: United States--US
GrantInformation_xml – fundername: Pfizer
  grantid: N/A
  funderid: http://dx.doi.org/10.13039/100004319
– fundername: ;
  grantid: N/A
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
9YT
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACMMV
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
AAFWJ
AALRI
AAYXX
CITATION
PHGZM
0R~
3V.
CGR
CUY
CVF
ECM
EIF
FRP
IGG
NPM
PKN
RHF
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-b486t-bcbcfd44f6230607f4d7efd22be8b07f2e760c5e61e05e69b22c1f024273468a3
IEDL.DBID 9YT
ISSN 0003-4967
1468-2060
IngestDate Thu Aug 21 18:38:19 EDT 2025
Fri Jul 11 15:37:01 EDT 2025
Fri Jul 25 11:07:32 EDT 2025
Fri Jul 25 10:53:55 EDT 2025
Sat Feb 15 01:21:18 EST 2025
Thu Apr 24 22:57:57 EDT 2025
Tue Jul 01 04:11:51 EDT 2025
Thu Apr 24 22:50:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Antirheumatic Agents
Cardiovascular Diseases
Arthritis, Rheumatoid
Language English
License This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b486t-bcbcfd44f6230607f4d7efd22be8b07f2e760c5e61e05e69b22c1f024273468a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Correspondence-2
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
ORCID 0000-0002-8962-5642
0000-0003-3009-6229
0000-0002-7794-6844
OpenAccessLink https://ard.bmj.com/content/82/4/575.full
PMID 36720582
PQID 2771159338
PQPubID 2041045
PageCount 3
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10086292
proquest_miscellaneous_2771636023
proquest_journals_2785871728
proquest_journals_2771159338
pubmed_primary_36720582
crossref_primary_10_1136_ard_2022_223406
crossref_citationtrail_10_1136_ard_2022_223406
bmj_journals_10_1136_ard_2022_223406
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-01
PublicationDateYYYYMMDD 2023-04-01
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Kidlington
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAbbrev Ann Rheum Dis
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2023
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
Elsevier Limited
BMJ Publishing Group
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: Elsevier Limited
– name: BMJ Publishing Group
References Ytterberg, Bhatt, Mikuls (R1) 2022; 386
Burmester, Nash, Sands (R3) 2021; 7
Charles-Schoeman, Wicker, Gonzalez-Gay (R6) 2016; 46
Charles-Schoeman, Buch, Dougados (R2) 2023; 82:119-29
Agca, Heslinga, Rollefstad (R5) 2017; 76
Charles-Schoeman (10.1136/ard-2022-223406_bib2) 2023; 82
American College of Cardiology (10.1136/ard-2022-223406_bib4)
Charles-Schoeman (10.1136/ard-2022-223406_bib6) 2016; 46
Ytterberg (10.1136/ard-2022-223406_bib1) 2022; 386
Agca (10.1136/ard-2022-223406_bib5) 2017; 76
Burmester (10.1136/ard-2022-223406_bib3) 2021; 7
References_xml – volume: 82:119-29
  year: 2023
  ident: R2
  article-title: Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard-2022-222259
– volume: 46
  start-page: 261
  year: 2016
  ident: R6
  article-title: Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2016.05.014
– volume: 386
  start-page: 316
  year: 2022
  ident: R1
  article-title: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2109927
– volume: 76
  start-page: 17
  year: 2017
  ident: R5
  article-title: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-209775
– volume: 7
  year: 2021
  ident: R3
  article-title: Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
  publication-title: RMD Open
  doi: 10.1136/rmdopen-2021-001595
– volume: 7
  start-page: e001595
  year: 2021
  ident: 10.1136/ard-2022-223406_bib3
  article-title: Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
  publication-title: RMD Open
  doi: 10.1136/rmdopen-2021-001595
– volume: 386
  start-page: 316
  year: 2022
  ident: 10.1136/ard-2022-223406_bib1
  article-title: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2109927
– ident: 10.1136/ard-2022-223406_bib4
– volume: 46
  start-page: 261
  year: 2016
  ident: 10.1136/ard-2022-223406_bib6
  article-title: Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2016.05.014
– volume: 82
  start-page: 119
  year: 2023
  ident: 10.1136/ard-2022-223406_bib2
  article-title: Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard-2022-222259
– volume: 76
  start-page: 17
  year: 2017
  ident: 10.1136/ard-2022-223406_bib5
  article-title: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-209775
SSID ssj0000818
Score 2.4691367
SourceID pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 575
SubjectTerms Antirheumatic Agents
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid
Arthritis, Rheumatoid - chemically induced
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Cardiology
Cardiovascular disease
Cardiovascular Diseases
Cardiovascular Diseases - chemically induced
Clinical trials
Coronary vessels
Heart Disease Risk Factors
Humans
Incidence
Letter
Patients
Pyrroles - adverse effects
Rheumatoid arthritis
Risk Factors
Surveillance
Treatment Outcome
Vein & artery diseases
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZokRAXxLuBgozUA5fQjeP4cUIIURWkcqLS3iLbsbWp2KTsZn9L_25nHGfLFi2XSJHtyM6MPTP2528IOfFNYQLYwZx7I3Ouuc81WPFcKxMqqx2EFHh3-OKnOL_kP-bVPG24rROscloT40Ld9A73yE-ZVBU495Kpz9d_cswahaerKYXGAXmI1GUI6ZJzebcSq0JNGfO4FjJR-xSlOEVEKkMkO5hHjumODuzyatc2_eNw3sdN_mWIzp6SJ8mDpF9GkT8jD3z3nDy6SGfkL8jN93jxkfaBuh2wKUUYOQV9ad0C9wRp31HcaY9ZRbH60lz1K2owRfPa328cmZ7W0ICCy0iHPhjXDm3XWrpa-A34vX3bUNDDRWRJotONS5oAYEv_klyeffv19TxP6Rdyy5UYcuusCw3nQWCYMpOBN9KHhjHrlYVX5qWYucqLws_gqS1jrgho82XJhTLlK3LY9Z0_IlQEUaIrUTlecMMb7VgQwVkuheVl4Bk5gd9fp-mzrmNkUooaBlqjlOpRShn5NMmndonCHDNp_N7f4OO2wfXI3rG_6vEk8Lt-MCnBY9YQxu8pnnQyIx-2xTA_8dDFdL7fjJ9ATjZWZuT1qD7brpRCslmlWEbUjmJtKyD3925J1y4iB3gRY1HN3vy_X2_JYxhjOUKNjsnhsNr4d-BFDfZ9nCq3txAc5Q
  priority: 102
  providerName: ProQuest
Title Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
URI https://ard.bmj.com/content/82/4/575.full
https://www.ncbi.nlm.nih.gov/pubmed/36720582
https://www.proquest.com/docview/2771159338
https://www.proquest.com/docview/2785871728
https://www.proquest.com/docview/2771636023
https://pubmed.ncbi.nlm.nih.gov/PMC10086292
Volume 82
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED-WFkpfxr6XrQsa9GEvTmNZlqzHrrR0g5Qx2pE9GUuWiEtjj8T5W_rv9s4f6dIR2IuN0Ydl3cl3J939DuDY5WHmUQ4GwmUqEFq4QKMUD3SS-dhoiyYFxQ5Pr-Tljfg-i2cdWDTFwuC0jM3ito1mIHymsj5J-IlAwz0e0470APYpJwl5b-nf148_3SRM-uR4QkvVofiEkaQukRfQ5kJJiOLrEA4iqfgkJuy9Ab5rWyL9o2Y-9Zb8S_xcvIDnnd7ITltCv4RnrnwFB9PuZPw13H9rwh1Z5ZndcjFl5DzOkEsKO6edQFaVjPbXm1yiVH2R3VZLllFi5pV72rjBd1phA4aKIqsrn9miLsrCsOXcrVHbrYqcIffNG2wk1sdZss7ta-HewM3F-fXZZdAlXQiMSGQdGGusz4XwkoyTifIiV87nnBuXGHzkTsmJjZ0M3QSv2nBuQ0-SXkVCJln0FvbKqnTvgUkvI1IgYitCkYlcW-6lt0YoaUTkxRCOcfrTbtGs0sYeiWSKH5oSwdKWYEMY9_RJbQdcTvkz7nY3-LJp8KfF7Nhd9agn-OM4uFKoJ2s03ncUJzGamYpj8edNMa5KOmrJSlet2y4IiY1HQ3jXss9mKD33DSHZYqxNBUL83i4pi3mD_B02FqjmH_5v5j7CIT5FraPREezVy7X7hDpUbUYwUDM1atbQCPZPz6bTX3j_en714-cDECsbwA
linkProvider BMJ Publishing Group Ltd
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbarQRcEG-2FDBSkbiEbmzHdg4I8Wi1S7srhFqptzR2bG0qNmn3IcQv4V_wG5nJY8sWLbdeIkW2Izvz-sYezxCy67Iw9WAHA-FSFYhYuCAGKx7EOvWRiS24FHh3eDiS_RPx5TQ63SC_27swGFbZ6sRKUWelxT3yPaZ0BOBeMf3-4jLAqlF4utqW0KjZ4tD9_AEu2-zd4DPQ9zVjB_vHn_pBU1UgMELLeWCssT4TwktE3z3lRaaczxgzTht4ZU7Jno2cDF0PnrFhzIYeTZniQuqUw3c3yZbg4Mp0yNbH_dHXb1e6X4e6rdEnYqmaZEIhl3sYA8swdh4MssACS5tmcr5qDf-BuNcjNf8yfQf3yN0Gs9IPNZPdJxuueEBuDZtT-Yfk16C6aklLT-1KeCvFwHUKHJrbMe5C0rKguLdf1THF7pP0vJzSFItCz9z1wVVuqRkMoABS6bz0qc3neZEbOh27BSDtMs8ocP64ystE2zuetAk5m7hH5ORGSPOYdIqycE8JlV5yBC-RFaFIRRZb5qW3RihpBPeiS3bh9yeNwM6SyhfiMoGFJkilpKZSl7xt6ZPYJmk61u74vn7Am-WAizpfyPquOy3Br-bBlAKMHnOu1zS3UtAlr5bNoBHwmCctXLmoP4FZ4Bjvkic1-yynwqVivUizLtErjLXsgNnGV1uKfFxlHQ8r7zdm2_-f10tyu388PEqOBqPDZ-QOrJfXgU47pDOfLtxzwHBz86IRHErOblpW_wDIT1tA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbaIlVcEP-EFjBSkbiE3diO7RwQQpRVl9KKA5X2FmLH1qZik3Y3K8ST8C48HTP52bJFy62XSJHtyM7MeD7bn2cIOXB5lHnwg6FwmQpFIlyYgBcPE5352CQWlhR4d_jkVB6diU-TeLJFfvd3YZBW2c-JzUSdVxb3yAdM6RjAvWJ64DtaxJfD0buLyxAzSOFJa59Oo1WRY_fzByzfFm_HhyDrV4yNPn79cBR2GQZCI7SsQ2ON9bkQXiISHyovcuV8zphx2sArc0oObexk5IbwTAxjNvLo1hQXUmccvrtNbikeR2hjaqKuvICOdJ-tTyRSdWGFIi4HyIZlyKIH1yww1dK2mZ2v-8V_wO51zuZfTnB0l9zp0Ct936rbPbLlyvtk96Q7n39Afo2bS5e08tSuEV0pUtgp6Gphp7gfSauS4i5_k9EUq8-y82pOM0wPvXDXGzdRphbQgAJcpXXlM1vURVkYOp-6JWDuqsgp2MC0idBE-9uetCOfzdxDcnYjgnlEdsqqdE8IlV5yhDGxFZHIRJ5Y5qW3RihpBPciIAfw-9POdBdpsyriMoWBpiiltJVSQN708kltFz4ds3h839zg9arBRRs5ZHPV_V7gV_1gSgFaTzjXG4p7ewjIy1UxzA144JOVrlq2n8B4cIwH5HGrPquucKnYMNYsIHpNsVYVMO74eklZTJv441GzDk7Y0__36wXZBQtNP49Pj_fIbRgubxlP-2Snni_dMwBztXneWA0l327aTP8A_fZeEA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+cardiovascular+risk+enrichment+on+incidence+of+major+adverse+cardiovascular+events+in+the+tofacitinib+rheumatoid+arthritis+clinical+programme&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Dougados%2C+Maxime&rft.au=Charles-Schoeman%2C+Christina&rft.au=Szekanecz%2C+Zolt%C3%A1n&rft.au=Giles%2C+Jon+T&rft.date=2023-04-01&rft.issn=0003-4967&rft.volume=82&rft.issue=4&rft.spage=575&rft.epage=577&rft_id=info:doi/10.1136%2Fard-2022-223406&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_ard_2022_223406
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon